trending Market Intelligence /marketintelligence/en/news-insights/trending/shhbywiavwkx1yoclqvthq2 content esgSubNav
In This List

Teva launches generic version of eye therapy in Canada

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Teva launches generic version of eye therapy in Canada

Teva Pharmaceutical Industries Ltd. said it launched Teva-Cyclosporine ophthalmic emulsion in Canada following approval by Health Canada.

The drugmaker said this is the first generic version of Allergan PLC's Restasis eye drops in Canada.

The therapy is indicated for treating dry eye disease. The condition causes burning, pain and redness in the eyes and can cause permanent vision damage if left untreated.

Restasis had annual sales of $46.5 million in Canada as of March, Teva stated, citing IQVIA sales data.

Allergan reported $255.8 million in global net revenues of Restasis for the first quarter, a decrease of 17.2% from the prior-year period.